Otolith Labs Announces Closing of $3.3 Million in Seed Financing; Receives “Breakthrough Device” Designation from FDA for Its Prescription Treatment for Vertigo
Otolith Labs , launched at the Halcyon Incubator, announced today it has received U.S. Food and Drug Administration (FDA) BREAKTHROUGH DEVICE designation for its medical device that is designed to be prescribed by physicians for the treatment of vertigo.
- Otolith Labs , launched at the Halcyon Incubator, announced today it has received U.S. Food and Drug Administration (FDA) BREAKTHROUGH DEVICE designation for its medical device that is designed to be prescribed by physicians for the treatment of vertigo.
- View the full release here: https://www.businesswire.com/news/home/20210624005166/en/
Otolith Labs' vertigo treatment device (Photo: Business Wire)
Otolith Labs noninvasive VESTIBULAR SYSTEM MASKING (nVSM) technology is designed to provide acute treatment for vestibulogenic vertigo. - The FDA Breakthrough Device designation will empower us to expedite the availability of our technology for the more than four million people with chronic vertigo who currently lack any viable alternative.
- Under the program, the FDA will provide Otolith Labs with priority review and interactive communication regarding clinical trial designs and commercialization decisions.